Cancers · 2023 · 31 citations · 51 references
MedicineBioinformaticsOncologyComputational BiologyDrug DiscoveryMolecular OncologyCancer Cell SignalingComputational OncologyDrug-target Interaction NetworksSignal Transduction In CancerCancer BioinformaticsCancer Cell Proliferation InhibitionCancer Drug Response PredictionKinase InhibitorsMalignant ProgressionMap KinasesSaliency MappingTumor Response Prediction
Deregulated protein kinases are crucial in promoting cancer cell proliferation and driving malignant cell signaling. Although these kinases are essential targets for cancer therapy due to their involvement in cell development and proliferation, only a small part of the human kinome has been targeted by drugs. A comprehensive scoring system is needed to evaluate and prioritize clinically relevant kinases. We recently developed CancerOmicsNet, an artificial intelligence model employing graph-based algorithms to predict the cancer cell response to treatment with kinase inhibitors. The performance of this approach has been evaluated in large-scale benchmarking calculations, followed by the experimental validation of selected predictions against several cancer types. To shed light on the decision-making process of CancerOmicsNet and to better understand the role of each kinase in the model, we employed a customized saliency map with adjustable channel weights. The saliency map, functioning as an explainable AI tool, allows for the analysis of input contributions to the output of a trained deep-learning model and facilitates the identification of essential kinases involved in tumor progression. The comprehensive survey of biomedical literature for essential kinases selected by CancerOmicsNet demonstrated that it could help pinpoint potential druggable targets for further investigation in diverse cancer types.
51
The Genotype-Tissue Expression (GTEx) project.
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Stephen Davies, Helen Reddy, Matilde Caivano et al. · Biochemical Journal · 2000 · 4.1K citations · Full text
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Hematology, Oncology +13
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Stephen Davies, Helen Reddy, Matilde Caivano et al. · Biochemical Journal · 2000 · 3.1K citations
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman, Sanna Herrgård, Daniel K. Treiber et al. · Nature Biotechnology · 2008 · 2.4K citations